Search results for " Paraganglioma"

showing 6 items of 6 documents

Malignant paraganglioma caused by a novel germline mutation of the succinate dehydrogenase D-gene--a case report.

2008

Background Paragangliomas of the head and neck are rare, mostly benign tumors. Approximately 10% to 15% of paragangliomas are caused by mutations in the succinate dehydrogenase (SDH) genes B, C, or D. These are often multifocal as part of paraganglioma syndromes and hormone secreting, and malignant particularly associated with mutations in SDHB. Methods and Results A 29-year-old man was seen with recurrent paraganglioma. The patient's father reportedly suffered from bilateral carotid body tumors. Imaging studies showed metastases in both lungs and the liver. There was no increased hormone production by the tumor. Sequence analysis of the SDH genes revealed a novel C to T nonsense mutation i…

AdultMalePathologymedicine.medical_specialtySDHBNonsense mutationmedicine.disease_causeRisk AssessmentSkull Base NeoplasmsPheochromocytomaParagangliomaTreatment RefusalGermline mutationParagangliomamedicineMalignant ParagangliomaHumansGenetic Predisposition to DiseaseGerm-Line MutationNeoplasm StagingMutationbusiness.industryBiopsy Needlemedicine.diseaseImmunohistochemistryPedigreeSuccinate DehydrogenaseOtorhinolaryngologyPositron-Emission TomographySDHDbusinessHeadneck
researchProduct

The Role of the Metabolome and Non-Coding RNA on Pheochromocytomas and Paragangliomas: An Update.

2022

Pheochromocytoma and paragangliomas (PPGL) are rare neuroendocrine tumors. In some patients they exhibit malignant behavior characterized by the presence of metastases, limiting treatment options and survival rates. Therapeutic options are limited to surgery, localized radiotherapy, and a few systemic therapies. However, in several recent studies, non-coding RNA molecules are gaining increasing attention as markers of malignancy for PPGL. The understanding of PPGL development molecular mechanisms has improved in the last years, with some of the epigenetic regulatory mechanisms such as DNA and histones methylation, being better understood than RNA-based mechanisms. Metabolome deregulation in…

Endocrinology Diabetes and MetabolismEpigenetics Metabolome MicroRNA Paraganglioma PheochromocytomaMolecular BiologyBiochemistryMetabolites
researchProduct

Cholesteatoma of the hypotympanum in a patient with Treacher Collins syndrome

2014

In the present article we report a cholesteatoma of the hypotympanum extending to the jugular foramen in a 16-year-old male with Treacher Collins syndrome. Preoperative imaging excluded jugular paraganglioma and set the diagnosis of cholesteatoma. We discuss the operative treatment via a large hypotympanotomy and creation of an open hypotympanic cavity. To the authors' knowledge this is the first description of hypotympanal cholesteatoma with such an extension, being treated through this approach.

Malemedicine.medical_specialtyAdolescentHypotympanotomyOpen cavityEar MiddlemedicineHumansCholesteatoma Middle Earbusiness.industryCholesteatomaGeneral Medicinemedicine.diseaseJugular paragangliomaMagnetic Resonance ImagingSurgerymedicine.anatomical_structureOtorhinolaryngologyMiddle earSurgeryTomography X-Ray ComputedbusinessTreacher Collins syndromeMandibulofacial DysostosisJugular foramenPreoperative imagingAuris Nasus Larynx
researchProduct

Malignant carotid paraganglioma: A case report

2019

Tumors of the carotid body are uncommon neoplasms that originate in the neuroectoderm. These tumors are slow growing but well vascularized and very destructive. Between 5% and 13% of carotid body tumors are malignant, behaving aggressively at the local level, invading the adjacent lymph nodes, and resulting in remote metastases. We present the case of a 60-year-old man who was examined for pain and paresthesias in his arm. Magnetic resonance imaging showed a large tumor in the left carotid space. Histologic study of a biopsy specimen from the tumor revealed that it was a paraganglioma. Further studies to determine the extent of disease detected metastases in bone and lung, confirming the tu…

Malemedicine.medical_specialtyLung NeoplasmsCarotid Body TumorMalignancyCarotid paragangliomaParaganglioma03 medical and health sciencesFatal Outcome0302 clinical medicineMalignant paragangliomaParagangliomaBiopsyHumansMalignant ParagangliomaMedicineHead and neck tumors030223 otorhinolaryngologyGeneral Environmental ScienceSpinal NeoplasmsLungmedicine.diagnostic_testbusiness.industryLiver NeoplasmsMagnetic resonance imagingMiddle Agedmedicine.diseaseClavicleMagnetic Resonance Imagingmedicine.anatomical_structure030220 oncology & carcinogenesisCervical VertebraeGeneral Earth and Planetary SciencesCarotid bodyRadiologyTomography X-Ray ComputedbusinessCarotid body tumorRadiología (English Edition)
researchProduct

Emerging Therapies in Pheochromocytoma and Paraganglioma: Immune Checkpoint Inhibitors in the Starting Blocks

2021

Pheochromocytoma and paraganglioma are neuroendocrine neoplasms, originating in the adrenal medulla and in parasympathetic and sympathetic autonomic nervous system ganglia, respectively. They usually present as localized tumours curable with surgery. However, these tumours may exhibit heterogeneous clinical course, ranging from no/minimal progression to aggressive (progressive/metastatic) behavior. For this setting of patients, current therapies are unsatisfactory. Immune checkpoint inhibitors have shown outstanding results for several types of solid cancers. We therefore aimed to summarize and discuss available data on efficacy and safety of current FDA-approved immune checkpoint inhibitor…

atezolizumabatezolizumab; avelumab; cemiplimab; durvalumab; immune checkpoint inhibitors; ipilimumab; nivolumab; paraganglioma; pembrolizumab; pheochromocytomadurvalumablcsh:MedicineIpilimumabReviewImmune checkpoint inhibitorPembrolizumabBioinformaticsimmune checkpoint inhibitorsPheochromocytomaAvelumabparaganglioma03 medical and health sciences0302 clinical medicineParagangliomaAtezolizumabMedicineipilimumabAte-zolizumab030304 developmental biologynivolumab0303 health sciencesbusiness.industrylcsh:RGeneral Medicinemedicine.diseasepheochromocytomaClinical trial030220 oncology & carcinogenesisavelumabcemiplimabpembrolizumabNivolumabbusinessmedicine.drugJournal of Clinical Medicine
researchProduct

Imaging of cervical lymph node metastases in malignant jugular paraganglioma: Imaging of paraganglioma metastases

2009

Not available

medicine.medical_specialtyEar MiddleparagangliomaText miningParagangliomamedicineHumansLymph nodeParaganglioma Extra-Adrenalbusiness.industryJugular paragangliomamedicine.diseaseSensory SystemsRadiographyOtorhinolaryngologic Neoplasmsmedicine.anatomical_structureCarotid ArteriesOtorhinolaryngologylymphonodeLymphatic Metastasismalignant paragangliomaNeurology (clinical)RadiologyLymph NodesJugular VeinsbusinessMagnetic Resonance AngiographyNeck
researchProduct